What is this study about?
The aim of this study is to develop better biomarkers for diagnosis and treatment of Lewy body disorders. In particular, there is a need to understand how the contribution of co-existing Alzheimer’s disease may affect the diagnosis and clinical course of dementia with Lewy bodies (DLB).
What is involved?
This study will recruit a group of individuals with DLB.. There will be up to 6 office visits over the 5 years. Participants will have a comprehensive neurological evaluation which will include donation of blood, urine, and cerebrospinal fluid samples.
Who can participate?
An individual may be able to take part in the trial if he/she:
- Has been diagnosed with dementia with Lewy bodies (DLB)
- Speaks English or Spanish
- Is able to provide their own consent to participate in the study at the first visit
The U.S. National Institutes of Health